Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates

BACKGROUND: BAY81‐8973 (Kovaltry; Bayer, Berkeley, CA, USA) was reported with enhanced pharmacokinetic (PK) profiles compared with some other standard half‐life (SHL) factor VIII (FVIII) concentrates. Limited head‐to‐head comparative studies were conducted in a real‐world setting. OBJECTIVE: To make...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Kun, Zhen, Yingzi, Li, Gang, Wu, Xinyi, Chen, Zhenping, Wu, Runhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956787/
https://www.ncbi.nlm.nih.gov/pubmed/35356665
http://dx.doi.org/10.1002/rth2.12686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956787/
https://www.ncbi.nlm.nih.gov/pubmed/35356665
http://dx.doi.org/10.1002/rth2.12686

Ejemplares similares